Top 12 Breast cancer treatment startups in USA
Mar 28, 2026
|
Like
16
1
Funding: $280.8M
Triana Biomedicines is developing a platform to discover molecular "glues" for disease regulation. This technology identifies small molecules that facilitate interactions between two proteins (work like a glue). One such application aims to activate the innate protein degradation pathway to destroy disease-specific protein (for example in cancer cells). The company's lead candidate, TRI-611, a molecular degrader targeting ALK-positive anaplastic lymphoma kinase, is aimed at treating non-small cell lung cancer (NSCLC) and is capable of overcoming resistance observed with existing treatments. The company also has clinical trials in breast cancer in its pipeline. Pfizer is a major investor.
Triana Biomedicines is developing a platform to discover molecular "glues" for disease regulation. This technology identifies small molecules that facilitate interactions between two proteins (work like a glue). One such application aims to activate the innate protein degradation pathway to destroy disease-specific protein (for example in cancer cells). The company's lead candidate, TRI-611, a molecular degrader targeting ALK-positive anaplastic lymphoma kinase, is aimed at treating non-small cell lung cancer (NSCLC) and is capable of overcoming resistance observed with existing treatments. The company also has clinical trials in breast cancer in its pipeline. Pfizer is a major investor.
2
Funding: $220M
Paige.AI was one of the first startups to apply AI models to cancer care and has since developed numerous models used for tissue analysis, tissue subtyping and molecular biomarker discovery. Paige has developed several AI applications for diagnostic decision support in oncology pathology, including prostate cancer detection and diagnosis in whole-section prostate biopsy images, identifying and classifying breast cancer in whole-section biopsy and excisional breast specimens, detecting and classifying benign and malignant diseases throughout the gastrointestinal tract. Developed using Virchow and trained on over 1.5 million slides, the Paige PanCancer Suite helps pathologists identify the subtlest nuances of cancer progression in various tissue types, including rare cancers. Acquired by Tempus
Paige.AI was one of the first startups to apply AI models to cancer care and has since developed numerous models used for tissue analysis, tissue subtyping and molecular biomarker discovery. Paige has developed several AI applications for diagnostic decision support in oncology pathology, including prostate cancer detection and diagnosis in whole-section prostate biopsy images, identifying and classifying breast cancer in whole-section biopsy and excisional breast specimens, detecting and classifying benign and malignant diseases throughout the gastrointestinal tract. Developed using Virchow and trained on over 1.5 million slides, the Paige PanCancer Suite helps pathologists identify the subtlest nuances of cancer progression in various tissue types, including rare cancers. Acquired by Tempus
3
Funding: $208.3M
Halda is developing RIPTAC - a new class of precision anti-cancer drugs. RIPTAC technology binds two proteins: one specific to the tumor and one that performs an essential function. This protein-protein interaction enables to selective destruct cancer cells. Halda's portfolio includes oral therapeutic drugs for treatment of metastatic castration-resistant prostate cancer and breast cancer. Clinical trials have already demonstrated good tolerability of this new therapy and encouraging signs of anti-tumor activity, including reductions in prostate-specific antigen (PSA) levels and Response Evaluation Criteria in Solid Tumors (RECIST) responses in patients with advanced prostate cancer, many of whom have progressed after several prior therapies and exhausted available treatment options. Acquired by Johnson & Johnson
Halda is developing RIPTAC - a new class of precision anti-cancer drugs. RIPTAC technology binds two proteins: one specific to the tumor and one that performs an essential function. This protein-protein interaction enables to selective destruct cancer cells. Halda's portfolio includes oral therapeutic drugs for treatment of metastatic castration-resistant prostate cancer and breast cancer. Clinical trials have already demonstrated good tolerability of this new therapy and encouraging signs of anti-tumor activity, including reductions in prostate-specific antigen (PSA) levels and Response Evaluation Criteria in Solid Tumors (RECIST) responses in patients with advanced prostate cancer, many of whom have progressed after several prior therapies and exhausted available treatment options. Acquired by Johnson & Johnson
4
Funding: $112.3M
Insight Molecular Diagnostics (iMDx) develops and provides diagnostic tests for oncology. The company is developing three genetic tests: blood tests for breast and lung cancer and a urine test for bladder cancer. iMDx has also developed a blood-based transplant monitoring test that quantifies the concentration of donor cell-free DNA (dd-cfDNA) after transplantation. The company partners with biotech research laboratories and supplies them with tests intended exclusively for research purposes in oncology and transplantation research projects.
Insight Molecular Diagnostics (iMDx) develops and provides diagnostic tests for oncology. The company is developing three genetic tests: blood tests for breast and lung cancer and a urine test for bladder cancer. iMDx has also developed a blood-based transplant monitoring test that quantifies the concentration of donor cell-free DNA (dd-cfDNA) after transplantation. The company partners with biotech research laboratories and supplies them with tests intended exclusively for research purposes in oncology and transplantation research projects.
5
Funding: $106M
Totus Medicines develops precision oral therapeutics for cancer treatment. The company uses own drug discovery platform OmniDEL, which utilizes artificial intelligence/machine learning and innovative DNA-encoded covalent library technology to search for small molecule drugs. The startup conducts ultra-high-throughput cell-based screening of these molecules using its proprietary labeling technology for cellular analysis. The company's flagship drug, TOS-358, is a precision oral drug for the treatment of cancers with PI3Kα mutations (the most frequently mutated oncogene in a wide range of cancers, for which there are currently no drugs that provide potent, specific and long-lasting inhibition without significant toxicity). TOS-358 is currently in clinical trials for the treatment of hormone receptor-positive breast, endometrial and head and neck cancers expressing PI3K-alpha mutations.
Totus Medicines develops precision oral therapeutics for cancer treatment. The company uses own drug discovery platform OmniDEL, which utilizes artificial intelligence/machine learning and innovative DNA-encoded covalent library technology to search for small molecule drugs. The startup conducts ultra-high-throughput cell-based screening of these molecules using its proprietary labeling technology for cellular analysis. The company's flagship drug, TOS-358, is a precision oral drug for the treatment of cancers with PI3Kα mutations (the most frequently mutated oncogene in a wide range of cancers, for which there are currently no drugs that provide potent, specific and long-lasting inhibition without significant toxicity). TOS-358 is currently in clinical trials for the treatment of hormone receptor-positive breast, endometrial and head and neck cancers expressing PI3K-alpha mutations.
6
Funding: $34.3M
Anixa is a publicly-traded biotechnology company focused on harnessing the body's immune system in the fight against cancer. Anixa's therapeutic portfolio includes a cancer vaccine technology focused on the immunization against α-Lactalbumin to prevent triple negative breast cancer (TNBC), as well as a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology.
Anixa is a publicly-traded biotechnology company focused on harnessing the body's immune system in the fight against cancer. Anixa's therapeutic portfolio includes a cancer vaccine technology focused on the immunization against α-Lactalbumin to prevent triple negative breast cancer (TNBC), as well as a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology.
7
Funding: $18.8M
4D Path develops QPOR platform, designed to directly measure and quantify cell cycle abnormalities and tumor microenvironment dynamics to predict patient response to therapy. It uses hematoxylin and eosin (H&E)-stained biopsy images to instantly uncover hidden data, enabling biomarker profiling and stratification. While the company initially focuses on breast cancer, it is actively developing products for ovarian cancer, cervical cytology, skin cancer, and, more broadly, immunotherapy for various cancer types.
4D Path develops QPOR platform, designed to directly measure and quantify cell cycle abnormalities and tumor microenvironment dynamics to predict patient response to therapy. It uses hematoxylin and eosin (H&E)-stained biopsy images to instantly uncover hidden data, enabling biomarker profiling and stratification. While the company initially focuses on breast cancer, it is actively developing products for ovarian cancer, cervical cytology, skin cancer, and, more broadly, immunotherapy for various cancer types.
8
Funding: $5.9M
Cyrcadia Health, creator of the iTbra, offers a discreet insert that goes under any bra, and empowers women to enhance their monthly breast self-exam in their own home. Their patches detect circadian temperature changes within breast tissue, and uses machine-learning algorithms to collect data and communicate it to Cyrcadia Health.
Cyrcadia Health, creator of the iTbra, offers a discreet insert that goes under any bra, and empowers women to enhance their monthly breast self-exam in their own home. Their patches detect circadian temperature changes within breast tissue, and uses machine-learning algorithms to collect data and communicate it to Cyrcadia Health.
11
Funding: $3.7M
TeVido BioDevices uses the innovative process of 3D bio-printing of living human cells for use as implants or grafts targeting use in reconstructive surgery and wound care. TeVido will change the way reconstructive surgery is approached, starting by improving options for breast cancer survivors but expanding capability to others who suffer disfigurement and long to improve their self-esteem.
TeVido BioDevices uses the innovative process of 3D bio-printing of living human cells for use as implants or grafts targeting use in reconstructive surgery and wound care. TeVido will change the way reconstructive surgery is approached, starting by improving options for breast cancer survivors but expanding capability to others who suffer disfigurement and long to improve their self-esteem.
12
Whiterabbit has developed a line of products targeting the mammography space to enable early and accurate breast cancer detection.
★
See also:
